AstraZeneca plc (LON:AZN) declared a dividend on Friday, February 2nd, Upcoming.Co.Uk reports. Shareholders of record on Thursday, February 15th will be given a dividend of GBX 133.60 ($1.85) per share by the biopharmaceutical company on Monday, March 19th. This represents a dividend yield of 2.8%. The ex-dividend date of this dividend is Thursday, February 15th. This is a boost from AstraZeneca’s previous dividend of $68.90. The official announcement can be seen at this link.
AstraZeneca (LON AZN) opened at GBX 4,822 ($66.62) on Wednesday. The stock has a market capitalization of $60,820.00 and a price-to-earnings ratio of 2,819.88. AstraZeneca has a twelve month low of GBX 4,260 ($58.86) and a twelve month high of GBX 5,520 ($76.26).
In related news, insider Philip A. J. Broadley purchased 415 shares of the stock in a transaction dated Friday, February 2nd. The shares were acquired at an average cost of GBX 4,846 ($66.95) per share, for a total transaction of £20,110.90 ($27,785.16).
ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) to Issue Dividend Increase – GBX 133.60 Per Share” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/14/astrazeneca-plc-azn-to-issue-dividend-increase-gbx-133-60-per-share.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.